Arecor Therapeutics unveils Tetris acquisition plans and focus on key product Ogluo

Arecor Therapeutics’ Sarah Howell joins Katie to talk about its acquisition of Tetris Pharma for £6mln.

Howell explains how this decision has been inspired to accelerate its commercial aspirations.

Tetris has developed and launched an injectable product called Ogluo for people at risk of severe hypoglycaemia that would sit alongside Arecor’s own fledgling treatments for diabetes.

© 2022 The Latest StockMarket News and Interviews